CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
OPERATING EXPENSES
General and administrative	$ 159	$ 55	$ 374	$ 437
Research and development	386	446	765	823
Total operating expenses	545	501	1,139	1,260
Interest and other expense, net	61	20	70	56
Loss from operations before taxes	606	521	1,209	1,316
Income tax benefit	(8)	(34)	(18)	(60)
NET LOSS	598	487	1,191	1,256
Less: Net Loss attributable to the noncontrolling interest	0	(946)	0	(946)
Net Loss attributable to Capstone Therapeutics Corp. stockholders	$ 598	$ (459)	$ 1,191	$ 310
Per Share Information:
Net loss, basic and diluted, attributable to Capstone Therapeutic Corp. stockholders (in dollars per share)	$ 0.01	$ (0.01)	$ 0.03	$ 0.01
Basic and diluted shares outstanding (in shares)	52,331	40,885	44,743	40,885